iBio Sets 2025 Annual Meeting: Director Elections, Auditor Ratification on Docket

Ticker: IBIO · Form: DEF 14A · Filed: 2025-10-06T00:00:00.000Z

Sentiment: neutral

Topics: Biotechnology, Corporate Governance, Proxy Statement, Director Election, Executive Compensation, Auditor Ratification, Annual Meeting, SEC Filing

Related Tickers: IBIO

TL;DR

**IBIO's 2025 proxy statement is a routine governance check, but re-electing CEO Brenner is a vote of confidence in the current scientific direction – expect stability, not fireworks.**

AI Summary

iBio, Inc. (IBIO) is holding its 2025 Annual Meeting of Stockholders on November 20, 2025, in San Diego, California. Stockholders will vote on four key proposals: the re-election of two Class II directors, Dr. Martin Brenner and Dr. Alexandra Kropotova, to serve three-year terms expiring in 2028; the ratification of Grassi & Co., CPAs, P.C. as the independent registered public accounting firm for the fiscal year ending June 30, 2026; an advisory, non-binding vote on named executive officer compensation (Say-on-Pay); and an advisory, non-binding vote on the frequency of future executive compensation advisory votes, with the Board recommending 'ONE YEAR'. Dr. Brenner, CEO and CSO since June 2023 and January 2021 respectively, was appointed to the Board in May 2024. Dr. Kropotova, a director since October 2020, chairs the Nominating and Corporate Governance Committee. The Board of Directors unanimously recommends a 'FOR' vote on all proposals, emphasizing the nominees' integrity, judgment, and business acumen.

Why It Matters

This DEF 14A filing outlines critical governance decisions for iBio, Inc., directly impacting investor confidence and strategic direction. The re-election of Dr. Martin Brenner, CEO and CSO, signals continuity in leadership and scientific strategy, which is crucial for a biotech firm. Ratifying Grassi & Co. ensures financial oversight, while the Say-on-Pay and Say-on-Frequency votes provide stockholders a voice on executive compensation, aligning management incentives with shareholder interests. In the competitive biotech landscape, stable governance and clear executive compensation practices are vital for attracting and retaining talent and capital.

Risk Assessment

Risk Level: low — The filing primarily details routine corporate governance matters for the 2025 Annual Meeting, including director elections and auditor ratification. There are no immediate red flags or contentious proposals that suggest significant financial or operational risk. The Board's recommendations are standard, indicating a stable, predictable corporate agenda.

Analyst Insight

Investors should review the biographies of Dr. Martin Brenner and Dr. Alexandra Kropotova to understand their qualifications and track records, as their re-election impacts leadership continuity. Pay close attention to the Say-on-Pay proposal to ensure executive compensation aligns with performance, and consider voting for a 'ONE YEAR' frequency for future advisory votes to maintain regular oversight.

Financial Highlights

debt To Equity
N/A
revenue
$N/A
operating Margin
N/A%
total Assets
$N/A
total Debt
$N/A
net Income
$N/A
eps
$N/A
gross Margin
N/A%
cash Position
$N/A
revenue Growth
+N/A%

Executive Compensation

NameTitleTotal Compensation
Dr. Martin BrennerChief Executive Officer and Chief Scientific Officer$N/A
Dr. Alexandra KropotovaDirector$N/A

Key Numbers

Key Players & Entities

FAQ

What are the key proposals for iBio's 2025 Annual Meeting of Stockholders?

At iBio's 2025 Annual Meeting, stockholders will vote on four key proposals: the election of two Class II directors (Dr. Martin Brenner and Dr. Alexandra Kropotova), the ratification of Grassi & Co., CPAs, P.C. as the independent auditor, an advisory vote on named executive officer compensation (Say-on-Pay), and an advisory vote on the frequency of future executive compensation advisory votes.

When and where will iBio's 2025 Annual Meeting be held?

iBio's 2025 Annual Meeting of Stockholders will be held on November 20, 2025, at 1:00 p.m. Pacific Time. The meeting will take place at 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121.

Who are the director nominees for iBio's Class II directors?

The two nominees for Class II director at iBio's 2025 Annual Meeting are Dr. Martin Brenner, who also serves as the Company's CEO and CSO, and Dr. Alexandra Kropotova, who is currently the Chair of the Nominating and Corporate Governance Committee.

What is the Board of Directors' recommendation for the frequency of future executive compensation advisory votes for iBio?

The Board of Directors of iBio recommends a vote 'FOR EVERY "ONE YEAR"' as the frequency for future executive compensation advisory votes, indicating a preference for annual Say-on-Frequency votes.

Who is iBio's independent registered public accounting firm for the fiscal year ending June 30, 2026?

iBio's Board of Directors recommends the ratification of Grassi & Co., CPAs, P.C. as the independent registered public accounting firm for the Company's fiscal year ending on June 30, 2026.

What is the record date for voting at iBio's 2025 Annual Meeting?

The record date for determining stockholders entitled to notice of and to vote at iBio's 2025 Annual Meeting is the close of business on October 3, 2025.

How can iBio stockholders submit their proxy votes?

iBio stockholders can submit their proxy votes via the internet or telephone by following instructions on the proxy card, or by signing, dating, and returning the enclosed proxy card by mail. The deadline for internet and telephone votes is 11:59 p.m. Eastern Time on November 19, 2025.

What is Dr. Martin Brenner's background and experience at iBio?

Dr. Martin Brenner has served as iBio's CEO since June 22, 2023, interim CEO from January 20, 2023, and CSO since January 18, 2021. He was appointed to the Board of Directors on May 9, 2024, effective June 1, 2024, bringing extensive experience in drug discovery and development from companies like AstraZeneca, Eli Lilly, Pfizer, and Merck Research Laboratories.

What is the significance of the Say-on-Pay proposal for iBio stockholders?

The Say-on-Pay proposal allows iBio stockholders to cast an advisory, non-binding vote on the compensation of the Company's named executive officers. This provides stockholders a direct voice on executive pay practices and helps align management incentives with shareholder interests.

Are there any other matters to be voted on at iBio's 2025 Annual Meeting?

The Board of Directors of iBio states that it knows of no other business that will come before the 2025 Annual Meeting beyond the four listed proposals: director elections, auditor ratification, Say-on-Pay, and Say-on-Frequency.

Industry Context

iBio, Inc. operates within the biotechnology sector, focusing on developing and commercializing biopharmaceutical products. This industry is characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. Companies in this space often compete on innovation, intellectual property, and the ability to navigate complex clinical trials and regulatory approvals.

Regulatory Implications

As a biotechnology company, iBio is subject to stringent regulations from bodies like the U.S. Food and Drug Administration (FDA). The success of its product candidates hinges on successful clinical trials and regulatory approvals, which are inherently uncertain and time-consuming. Any delays or failures in the regulatory process can significantly impact the company's financial performance and stock value.

What Investors Should Do

  1. Review the qualifications and independence of the director nominees, Dr. Martin Brenner and Dr. Alexandra Kropotova, before voting on Proposal 1.
  2. Consider the role and independence of Grassi & Co., CPAs, P.C. when voting on the ratification of the independent auditor (Proposal 2).
  3. Evaluate the company's executive compensation practices and vote on the advisory 'Say-on-Pay' proposal (Proposal 3) based on alignment with company performance.
  4. Determine the preferred frequency for future 'Say-on-Pay' votes and cast your vote accordingly (Proposal 4), with the Board recommending 'ONE YEAR'.

Key Dates

Glossary

DEF 14A
A proxy statement filed with the U.S. Securities and Exchange Commission (SEC) by publicly traded companies. It contains information about the company's annual meeting of stockholders, including details on director nominees, executive compensation, and proposals to be voted on. (This document provides the core information for understanding the company's governance and upcoming shareholder decisions.)
Class II Directors
In a staggered board structure, directors are divided into classes, with each class elected for a multi-year term. Class II directors are those whose terms are up for election in the current year. (This filing concerns the re-election of two Class II directors, Dr. Martin Brenner and Dr. Alexandra Kropotova, to serve until 2028.)
Say-on-Pay
An advisory, non-binding shareholder vote on the compensation of the company's named executive officers. (Shareholders will have the opportunity to express their opinion on the executive compensation practices of iBio, Inc.)
Independent Registered Public Accounting Firm
An external audit firm that is independent of the company it audits, responsible for examining the company's financial statements. (Shareholders are asked to ratify the appointment of Grassi & Co., CPAs, P.C. as iBio's auditor for the upcoming fiscal year.)
Staggered Board
A corporate governance practice where directors are elected for overlapping terms, rather than all at once. This typically results in only a portion of the board being up for election each year. (iBio's Board of Directors is divided into three classes, with Class II directors standing for election at the 2025 Annual Meeting.)

Year-Over-Year Comparison

This filing pertains to the 2025 Annual Meeting. Specific comparative financial metrics and risk factor updates from the previous year's DEF 14A are not detailed within this excerpt. However, the focus on re-electing key directors and ratifying auditors suggests a continuity in governance and financial oversight strategy.

Filing Stats: 4,711 words · 19 min read · ~16 pages · Grade level 12 · Accepted 2025-10-06 17:15:58

Key Financial Figures

Filing Documents

Executive Compensation

Executive Compensation 26 Pay vs. Performance 41

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 45 Transactions With Related Persons, Promoters and Certain Control Persons 48 Additional Information About These Proxy Materials and Voting 50 Annual Report on Form 10-K 56 Notice Regarding Delivery of Stockholder Documents ("Householding" Information) 57 Stockholder Proposals for the 2026 Annual Meeting 58 Other Matters 59 Proxy Statement 1 Table of Contents Proxy Summary PROXY Summary Directors and Director Nominees Name and Position Age Director Since Independent Committee Memberships Audit Compensation Nominating & Corporate Governance DR. MARTIN BRENNER Chief Executive Officer and Chief Scientific Officer of iBio 55 June 2024 WILLIAM D. CLARK Former President and Chief Executive Officer of Vibrant Biomedicines, Inc. 57 August 2021 DR. ALEXANDRA KROPOTOVA Executive Vice President and Chief Medical Officer of SAb Biotherapeutics 53 October 2020 EVERT SCHIMMELPENNINK Chief Executive Officer and President of LENZ Therapeutics, Inc. 53 June 2021 GARY SENDER Former Chief Financial Officer of Nabriva Therapeutics plc 63 October 2020 DAVID ARKOWITZ Chief Financial Officer of Alkeus Pharmaceuticals, Inc. 64 November 2024 ANT NIO PARADA C hief Executive Officer of FairJourney Biologics 57 November 2024 Chair Member Chair of the Board of Directors 2 iBio, Inc. Table of Contents Proposal 1 Election of Directors PROPOSAL 1 Election of Directors The Board of Directors currently consists of seven (7) directors and is divided into three classes. Each class serves for a term ending at the third annual meeting of stockholders following the election of such class, with the terms of office of the respective classes expiring in successive years. Directors in Class II will stand for election this year at the 2025 Annual Meeting, directors in Class III will stand for election at the 2026 Annual Meeting of Stockhold

View on Read The Filing